Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
about
The emergence of biosimilar insulin preparations--a cause for concern?Biosimilar drugs: Current statusRegulatory considerations in oncologic biosimilar drug developmentCombination therapeutics in complex diseasesClinical trial design in biosimilar drug development.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Avidity-controlled delivery of angiogenic peptides from injectable molecular-recognition hydrogelsUpdate on the safety and bioequivalence of biosimilars - focus on enoxaparin.Is the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review.Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.The hope and reality of long-acting hemophilia products.The safety of switching between therapeutic proteins.Similar biotherapeutic products: overview and reflections.Novel products for haemostasis.Biosimilars: clinical interpretation and implications for drug development.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropeniaXM17 Follitropin Alfa (Ovaleap(®)): A Review in Reproductive Endocrine Disorders.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Interchangeability of Biosimilars: A European Perspective.Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.Projecting expenditure on medicines in the UK NHS.Analytical and Biological Characterization of a Noninnovator Insulin Glargine and the Originator Drug Product.Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.Biologicals and biosimilars: safety issues in Europe.Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.Insights of biosimilars through SWOT analysis.The advent of biosimilar therapies in rheumatology—“O Brave New World”
P2860
Q26824362-AC04ACB7-6288-4CE1-8B08-2800E065446CQ27004314-638964E2-7A96-4E5A-9D55-EE16368CD37FQ27027947-D7C792FC-FE6D-44FA-81E3-7774F364EB82Q28076891-3795094E-EE7C-4DF6-A871-0FA0BC7A1448Q30423748-A79DAC62-D231-4EB6-B8B7-A662EC259D74Q33881234-FE665693-7C31-4AB6-9540-2C07BCBF2AB5Q34063536-E8DE953D-6714-48EB-99A7-C830565E87AEQ34352446-5590819A-6D6B-45BB-8823-99F02D548130Q35103040-646F3C63-46F4-416C-856D-8FA81A893175Q35929084-FE50029B-E4C7-42E8-AAAD-10B2E6873B6AQ36331497-09ABB9D6-C7EC-4863-B437-8B4FB49C1A29Q37327298-6EADEFA6-8DF7-4576-8879-85FA06519765Q37990479-625CCA5F-6CCD-472E-81A8-DAB383E01EECQ38030980-F3E2FDDC-6A12-4C3D-A9D0-1B2D7977A9D4Q38067449-73BC5F76-D39C-4776-B412-A32343D634D7Q38206850-3E431032-5AAA-44F9-A88C-8E52EEBC4EC7Q38331244-14788AB8-ECC3-41E4-B95F-07D280F506AAQ38365041-D6716F47-3ACD-4AB2-AB8F-62ED05CAB3F1Q38626569-1FD7C721-9FA7-4680-8B62-5E009573D55BQ38876357-8854F92B-F48E-49CD-8731-8C9EF0F33E10Q38937842-15C48036-D708-424B-9400-78042D754ACBQ39000780-81036444-B15B-438E-A8F6-48BA1D006AA7Q39141802-83EE2278-40A8-43A7-9E57-A363C8B2FC2CQ39350064-700995E7-50E2-43B4-8BF8-088F7197D96BQ42618435-CB75507D-94DD-466B-955E-1450049D84FFQ47656264-2C8F0267-5F24-4182-BE79-C3ABBDD7E700Q47688424-F80C1EA2-9F66-4ABF-B6B7-045E07E827D2Q48104740-C538F71F-8CC9-4972-9868-74D6D2D2244DQ51320460-F31F75C1-E385-4905-A60A-AF43944D69EDQ51349679-4C8BC4C3-8B71-497A-A35C-F6CD19ED3D1CQ57752047-393ACDC0-7A5F-4C4F-A548-CE5D31F75AB6
P2860
Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Biosimilars of biological drug ...... and commercial considerations.
@ast
Biosimilars of biological drug ...... and commercial considerations.
@en
type
label
Biosimilars of biological drug ...... and commercial considerations.
@ast
Biosimilars of biological drug ...... and commercial considerations.
@en
prefLabel
Biosimilars of biological drug ...... and commercial considerations.
@ast
Biosimilars of biological drug ...... and commercial considerations.
@en
P2860
P1433
P1476
Biosimilars of biological drug ...... and commercial considerations
@en
P2093
George Dranitsaris
Kristine Dorward
P2860
P304
P356
10.2165/11593730-000000000-00000
P50
P577
2011-08-01T00:00:00Z
P5875
P6179
1042265294